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INTRODUCTION
Mammographically visible suspicious microcalcifications 
with no associated mass are usually diagnosed by 
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Objective: To evaluate the diagnostic outcomes of ultrasonography-guided core needle biopsy (US-CNB), US-guided 
vacuum-assisted biopsy (US-VAB), and stereotactic-guided vacuum-assisted biopsy (S-VAB) for diagnosing suspicious breast 
microcalcification. 
Materials and Methods: We retrospectively reviewed 336 cases of suspicious breast microcalcification in patients who 
subsequently underwent image-guided biopsy. US-CNB was performed for US-visible microcalcifications associated with a 
mass (n = 28), US-VAB for US-visible microcalcifications without an associated mass (n = 59), and S-VAB for mammogram-
only visible lesions (n = 249). Mammographic findings, biopsy failure rate, false-negative rate, and underestimation rate 
were analyzed. Histological diagnoses and the Breast Imaging Reporting and Data System (BI-RADS) categories were 
reported.
Results: Biopsy failure rates for US-CNB, US-VAB, and S-VAB were 7.1% (2/28), 0% (0/59), and 2.8% (7/249), respectively. 
Three false-negative cases were detected for US-CNB and two for S-VAB. The rates of biopsy-diagnosed ductal carcinoma in 
situ that were upgraded to invasive cancer at surgery were 41.7% (5/12), 12.9% (4/31), and 8.6% (3/35) for US-CNB, US-
VAB, and S-VAB, respectively. Sonographically visible lesions were more likely to be malignant (66.2% [51/77] vs. 23.2% 
[46/198]; p < 0.001) or of higher BI-RADS category (61.0% [47/77] vs. 22.2% [44/198]; p < 0.001) than sonographically 
invisible lesions.
Conclusion: Ultrasonography-guided vacuum-assisted biopsy is more accurate than US-CNB when suspicious microcalcifications 
are detected on US. Calcifications with malignant pathology are significantly more visible on US than benign lesions.
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stereotactic or excisional biopsy under wire localization 
(1-3). Ultrasonography (US) is limited for detecting 
microcalcifications, which is related to low contrast 
resolution; however, US detects microcalcifications 
associated with other findings, such as mass or ductal 
changes (4-6). In general, patients prefer sonographically-
guided procedures to mammographically-guided procedures, 
as patients tend to be more comfortable in the supine 
position, the breast is not compressed, and the procedure 
is less time-consuming. In addition, no ionizing radiation 
is used, the needle insertion site is more flexible, and real-
time observations can be made (7, 8). For these reasons, 
if microcalcifications are detected on US, US-guided core 
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biopsy (US-CNB) or US-guided vacuum-assisted biopsy (US-
VAB) is conducted for the diagnosis (5, 9-11).
When all of these findings are considered, the 
histopathological diagnosis is determined for suspicious 
microcalcifications detected on mammography using a 
variety of biopsy methods, including stereotactic VAB 
(S-VAB), US-CNB, US-VAB, or surgical biopsy, depending on 
the imaging findings and each patient’s clinical situation.
Several studies have reported on the diagnostic outcomes 
of stereotactic biopsy (12-14) and US-guided biopsy (5, 
9, 10, 15). However, no study has considered the overall 
consequences of image-guided methods for diagnosing 
microcalcifications.
The purpose of this study was to evaluate the success 
rate, malignancy rate, and diagnostic accuracy of US-
CNB, US-VAB, and S-VAB for diagnosing suspicious 
microcalcifications detected on mammography.
MATERIALS AND METHODS
This single-center retrospective study was approved by 
the Institutional Review Board of our hospital, and signed 
informed consent was obtained from all patients prior to 
their biopsy procedures.
Study Population
A retrospective review was performed of 10310 patients 
who underwent mammography between March 2009 and 
January 2011 at our institution. A total of 1836 patients 
were classified under Breast Imaging Reporting and Data 
System (BI-RADS) categories 4 and 5, and among these, 406 
patients with 407 lesions had microcalcifications without 
associated findings. All of these cases were recommended 
for biopsy; 15 patients were lost during follow-up or 
decided not to undergo biopsy. Fifty-five patients with 
56 lesions underwent surgical biopsies because of other 
scheduled surgeries or because of patient preference. 
Finally, 336 patients with 336 lesions who underwent 
image-guided biopsy were included in our study. Of the 336 
patients, 28 underwent US-CNB, 59 underwent US-VAB, and 
249 underwent S-VAB (Fig. 1). 
Imaging Technique
Mammography was performed with the GE Senographe 
DS full-field digital mammography system (GE Healthcare, 
Milwaukee, WI, USA) and the Lorad/Hologic Selenia full-
field digital mammography system (Lorad/Hologic, Danbury, 
CT, USA). Standard craniocaudal and mediolateral oblique 
views were routinely obtained along with magnified 
mammograms. 
Ultrasonography was performed using a high-resolution 
US unit (iU22, Philips Medical Systems, Bothell, WA, USA 
or Logiq 9, GE Medical Systems, Milwaukee, WI, USA) with 
12-MHz linear-array transducers by one of nine dedicated 
radiologists with 1–18 years of experience. All suspicious 
microcalcification clusters were evaluated on sonography 
before biopsy.
Biopsy Procedure and Management
The management protocol for suspicious 
microcalcifications without other mammographic features 
in our institution is US-CNB for microcalcifications with an 
associated mass (Fig. 2) and US-VAB for microcalcifications 
visible on US without an associated mass. If the 
correlation between US-visible microcalcifications and 
mammographically observed microcalcifications is uncertain, 
a radio-opaque marker is placed on the skin at the location 
of the US-visible microcalcification. The area is then 
reevaluated to confirm if the US-visible microcalcifications 
US-CNB
28 (8.3%)
Lost to follow-up
15 (3.7%)
BI-RADS 1, 2, 3
8474 (82.2%)
10310
Diagnostic mammography
US-VAB
59 (17.6%)
Image-guided biopsy
336 (82.8%)
Only 
microcalcification
406 (22.1%)
S-VAB
249 (74.1%)
Surgical biopsy
55 (13.5%)
Other positive
findings
1430 (77.9%)
BI-RADS 4, 5
1836 (17.8%)
Fig. 1. Study population. BI-RADS = Breast Imaging Reporting and 
Data System, S-VAB = stereotactic-guided vacuum assisted biopsy, 
US-CNB = ultrasonography-guided core needle biopsy, US-VAB = 
ultrasonography-guided vacuum assisted biopsy
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can be visualized on mammography (Fig. 3). S-VAB is used 
for microcalcifications visible only on mammography. The 
number of core samples is decided by each operator. An 
excisional biopsy was performed if the patient preferred 
surgical excision or was scheduled for another surgery. 
Except in cases where a patient or clinician requested a 
different procedure, all lesions included in this study were 
managed according to the above protocol.
All biopsy procedures were performed by one of nine 
dedicated radiologists with 1–18 years of experience. 
US-CNB was performed using a 14-gauge core needle 
(Stericut; TSK Laboratory, Tochigi, Japan). US-VAB and 
S-VAB were performed using 8- or 11-gauge vacuum probes 
(Mammotome; Ethicon Endo-Surgery, Inc., Cincinnati, OH, 
USA). S-VAB was performed in the lateral decubitus position 
(16) with the breast lesion facing up (Digital Stereotaxy 
with Senographe DS Interventional; GE Healthcare). A 
microclip was inserted at the biopsy site after S-VAB only. 
Specimen mammography was performed after biopsy in 
every case to confirm whether the microcalcifications of 
interest were successfully retrieved. All specimens with and 
without calcifications were sent separately for pathological 
examination.
In all cases, the histopathological results were 
correlated with mammographic findings by radiologists 
and pathologists. In cases of discordance, repeat biopsy 
or surgical excision was recommended. Patients with high-
risk lesions, such as atypical ductal hyperplasia (ADH), 
atypical lobular hyperplasia (ALH), lobular carcinoma in 
situ (LCIS), papilloma, radial scar, or malignant lesions, 
were recommended for surgical resection. Patients with 
concordant benign lesions were scheduled for repeat 
mammography at 6, 12, and 24 months. 
Follow-Up and Data Analysis
The clinical, histological, and imaging findings 
were reviewed, including the results from each biopsy 
and follow-up imaging studies. The size, number, 
distribution, morphology, and final BI-RADS category of 
the microcalcifications on mammography were compared 
among the three biopsy method groups. Biopsy failure was 
defined as technical failure of targeting or sampling of 
microcalcifications because of a vasovagal reaction in a 
patient, inability to visualize or access the target during 
biopsy, or absence of calcification on specimen radiography.
We evaluated the malignancy rate, histological 
underestimation (17), and false-negative results, which 
were based on patients who underwent surgery after biopsy 
Fig. 2. 68-year-old female patient with complaint of bloody nipple discharge from left breast.
A. Magnified mammogram of left breast reveals suspicious segmental coarse heterogeneous microcalcifications. B. Ultrasonogram of left breast 
shows hypoechoic mass with internal hyperechoic foci in upper outer aspect of left breast. 14-gauge ultrasonography-guided core needle biopsy 
was performed on mass, and final diagnosis was invasive ductal carcinoma.
A B
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Fig. 3. 54-year-old female patient who underwent screening mammography.
A. Magnified mammogram of left breast reveals suspicious segmental coarse heterogeneous microcalcifications. B. Ultrasonogram of left breast 
shows microcalcifications (arrows) at corresponding area of microcalcifications observed on mammography. C. Radio-opaque marker was placed 
on skin over lesion for confirmation, and left breast view was magnified. Ultrasonography (US)-visible microcalcifications are correlated with 
mammographically visualized microcalcifications. D. 11-gauge US-guided vacuum-assisted biopsy is performed. E. Specimen mammography 
confirms retrieval of microcalcifications. Diagnosis was ductal carcinoma in situ, which was also confirmed by post-partial mastectomy pathology.
A
C
E
B
D
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or who were followed-up with mammography for at least 
1 year after being diagnosed with a benign lesion. The 
malignancy rate was determined by dividing the number of 
biopsy-diagnosed ductal carcinoma in situ (DCIS) cases and 
invasive carcinoma cases by the total number of successfully 
performed biopsies that were followed by surgery or by 
more than 1 year of mammographic follow-up. The ADH 
underestimation rate was defined as the number of biopsy-
diagnosed ADH lesions that were upgraded to DCIS or 
invasive cancer at surgical excision divided by the number 
of biopsy-diagnosed ADH lesions. The DCIS underestimation 
rate was defined as the number of DCIS lesions upgraded 
to invasive cancer at surgical excision divided by the 
number of biopsy-diagnosed DCIS lesions. A false-negative 
result was defined as a final diagnosis of malignancy for a 
lesion previously diagnosed as benign by biopsy. The false-
negative rate was also defined as the number of false-
negative cases divided by the number of cases with a final 
diagnosis of malignancy. We also compared US-visible 
and US-invisible lesions by malignancy rate and BI-RADS 
category.
The chi-square test was performed to correlate the BI-
RADS final assessment category and malignancy rate with 
visibility on US and to compare the proportion of invasive 
carcinomas showing malignant pathology according to 
biopsy method. Statistical analyses were performed using 
SPSS 20.0 software (SPSS Inc., Chicago, IL, USA). P values 
< 0.05 were considered statistically significant. 
RESULTS 
The mean age of the 336 patients was 47.5 years (range, 
23–68 years). The mammographic features are summarized 
in Table 1. The breast tissue of most patients showed a 
Table 1. Mammographic Features of Microcalcifications According to Biopsy Methods, n (%)
US-CNB (n = 28) US-VAB (n = 59) S-VAB (n = 249)
Age (years)* 49.2 (29–70) 46.5 (23–67) 47.6 (25–68)
Parenchymal density 
Entirely fatty 0 (0) 0 (0) 0 (0)
Scattered fibroglandular 2 (7.1) 1 (1.7) 6 (2.4)
Heterogeneously dense 25 (89.3) 57 (96.6) 233 (93.6)
Extremely dense 1 (3.6) 1 (1.7) 10 (4.0)
Calcifications
Extent (mm)* 32.5 (5–100) 23.8 (5–91) 14.3 (3–62)
Number 
< 15 3 (10.7) 10 (17.0) 39 (15.7)
15–50 6 (21.4) 19 (32.2) 115 (46.2)
> 50 19 (67.9) 30 (50.9) 95 (38.2)
Distribution
Grouped 11 (39.3) 24 (40.7) 166 (66.7)
Linear 0 (0) 2 (3.4) 14 (5.6)
Segmental 13 (46.4) 28 (47.5) 48 (19.3)
Regional 2 (7.1) 5 (8.5) 21 (8.4)
Diffuse 2 (7.1) 0 (0) 0 (0)
Morphology
Amorphous 2 (7.1) 9 (15.3) 63 (25.3)
Round 3 (10.7) 18 (30.5) 133 (53.4)
Coarse heterogeneous 3 (10.7) 17 (28.8) 46 (18.5)
Fine linear 1 (3.6) 0 (0) 0 (0)
Fine pleomorphic 19 (67.9) 15 (25.4) 7 (2.8)
BI-RADS category
4a 6 (21.4) 30 (50.9) 201 (80.7)
4b 4 (14.3) 16 (27.1) 33 (13.3)
4c 10 (35.7) 10 (17.0) 15 (6.0)
5 8 (28.6) 3 (5.1) 0 (0)
*Mean (range). BI-RADS = Breast Imaging Reporting and Data System, S-VAB = stereotactic-guided vacuum-assisted biopsy, US-CNB = 
ultrasonography-guided core needle biopsy, US-VAB = ultrasonography-guided vacuum-assisted biopsy
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heterogeneously dense pattern. The assigned BI-RADS 
assessment category differed according to biopsy method. 
Category 4a was the most commonly assigned category in 
the US-VAB and S-VAB groups, whereas category 4c was the 
most commonly assigned in the US-CNB group. The mean 
number of specimens obtained per lesion was 6.6 (range, 
4–15) with US-CNB; 12.0 (range, 6–33) with US-VAB; and 
12.6 (range, 3–53) with S-VAB. The US features of the 28 
US-CNB lesions are summarized in Table 2.
A total of 275 patients underwent surgery after biopsy 
or were followed-up for at least 1 year with mammography 
after being diagnosed with a benign lesion. Of these 
275 lesions, 97 were malignant on pathology (21 cases 
of invasive cancer and 76 cases of DCIS), and 178 were 
benign. Of the benign lesions, benignity was confirmed by 
surgical excision in 17 cases and presumed in 161 cases by 
the stability observed on follow-up mammography, with a 
mean follow-up period of 1173.8 days (range, 385–1924 
days).
Biopsy Failure Rate, Malignancy Rate, False-Negative 
Rate, and Underestimation Rate
Of the 28 US-CNB lesions, biopsy failed in two patients 
(7.1%) because the calcifications were absent on specimen 
radiography. These two patients underwent re-biopsy, 
one with S-VAB following benign pathology and one with 
excisional biopsy following a DCIS result. Seven procedures 
failed (2.8%) during S-VAB for the 249 lesions because of 
vasovagal reactions (n = 2) or inaccessibility of lesions due 
to inadequate breast thickness under compression (n = 5). 
These seven patients underwent excisional biopsies, and all 
results were benign. No US-VAB biopsy failures occurred.
Of the 327 successful biopsy cases, the histological 
results of the initial biopsy were benign in 217 cases; 214 
were considered concordant with the imaging findings and 
three were considered discordant with benign results. Three 
patients underwent re-biopsy, two with US-VAB and one 
with excisional biopsy, and the final pathological results 
were all DCIS.
The malignancy rates according to BI-RADS category 
were 17.9% (33/184) for category 4a, 53.2% (25/47) 
for category 4b, 84.8% (28/33) for category 4c, and 
100% (11/11) for category 5. The malignancy rates were 
83.3%, 58.5%, and 23.7% for US-CNB, US-VAB, and S-VAB, 
Table 2. US Features of US-CNB Lesions, n (%)
US-CNB (n = 28)
Size (mm)* 20 (6–100)
Shape
Oval 9 (32.1)
Round 1 (3.6)
Irregular 18 (64.3)
Orientation
Parallel 25 (89.3)
Not parallel 3 (10.7)
Margin
Circumscribed 2 (7.1)
Indistinct 14 (50)
Angular 3 (10.7)
Microlobulated 9 (32.1)
Echogenicity
Hypoechoic 22 (78.6)
Isoechoic 2 (7.1)
Heterogeneous 4 (14.3)
Posterior features
No posterior features 19 (67.9)
Enhancement 1 (3.6)
Shadowing 8 (28.6)
Calcifications
Calcifications in mass 27 (96.4)
Calcifications outside of mass 1 (3.6)
*Mean (range). US-CNB = ultrasonography-guided core needle 
biopsy
Table 3. False-Negative Diagnoses after Image-Guided Biopsy
Patient 
Age
(Years)
BI-RADS 
Category
Type of 
Biopsy
First 
Histopathological 
Diagnosis
Calcification 
Retrieval
Imaging-
Histologic 
Concordance
Interval 
(Days)*
Type of 
Re-Biopsy
Final 
Histopathological 
Diagnosis
29 4c US-CNB Stromal fibrosis Yes No 14 US-VAB DCIS
47 4c US-CNB Stromal fibrosis No No 6 Excisional biopsy DCIS
59 5 US-CNB Florid ductal hyperplasia Yes No 13 US-VAB DCIS
59 4b S-VAB Fibrocystic disease Yes No 7 Excisional biopsy DCIS
43 4a S-VAB Fibrocystic change Yes Yes 1106 S-VAB DCIS
*Time interval between initial biopsy and re-biopsy. BI-RADS = Breast Imaging Reporting and Data System, DCIS = ductal carcinoma 
in situ, S-VAB = stereotactic-guided vacuum assisted biopsy, US-CNB = ultrasonography-guided core needle biopsy, US-VAB = 
ultrasonography-guided vacuum assisted biopsy
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respectively. Among lesions with malignant pathology, 
invasive carcinoma was more frequent in the US-CNB group 
(45.0%, 9/20) than in the US-VAB (16.1%, 5/31) and S-VAB 
groups (17.4%, 8/46).
The false-negative rates were 15.0% (3/20), 0% 
(0/31), and 4.3% (2/46) for US-CNB, US-VAB, and S-VAB, 
respectively. Three false-negative cases for US-CNB and two 
false-negative cases for S-VAB are summarized in Table 3. 
Four patients underwent immediate re-biopsy due to the 
absence of calcifications on specimen mammography (n = 
1) (Fig. 4) and image-pathology discordance (n = 3), and 
all were DCIS. The other case was thought to be image-
pathology concordant after benign biopsy results. The 
patient’s screening mammography 3 years later revealed an 
increased extent of the previous suspicious calcifications, 
and the re-biopsy result was DCIS. The ADH underestimation 
rates were 0% (0/1) for US-CNB, 0% (0/2) for US-VAB, and 
20% (1/5) for S-VAB. The DCIS underestimation rates were 
41.7% (5/12), 12.9% (4/31), and 8.6% (3/35) for US-CNB, 
US-VAB, and S-VAB, respectively.
For the other high-risk lesions that were excised, one 
ALH diagnosis at S-VAB was confirmed to be ALH after 
excision. Three cases of LCIS at S-VAB were confirmed 
to be malignant (two DCIS and one mixed solid papillary 
carcinoma) after excision.
BI-RADS Final Assessment Category and Histologic 
Diagnosis According to US Visibility 
The correlation between visibility on US and the BI-
RADS final assessment category or histological diagnosis 
is shown in Table 4. Malignant pathology and a higher BI-
RADS category were more frequent in US-visible lesions (p 
< 0.001). However, with regard to the proportion of cases 
showing malignant pathology, invasive cancer was 25.5% 
(13/51) in US-visible lesions and 17.4% (8/46) in US-
invisible lesions (p = 0.334). 
DISCUSSION
Our results demonstrate the overall diagnostic outcomes 
of US-CNB, US-VAB, and S-VAB. No previous study has 
reported overall outcomes of image-guided breast biopsy 
methods after establishing clear criteria at a single center 
during the same timeframe, although there have been 
many reports summarizing biopsy methods individually or 
comparing two biopsy methods (2, 5, 9, 10, 12-15).
The microcalcification retrieval rates in our study were 
92.9% for US-CNB and 100% for US-VAB and S-VAB, which 
were within the range of previous studies (5, 10, 11, 15). 
Among the seven biopsy failure cases (2.8%) in S-VAB, 
biopsy was technically infeasible in five lesions (2.0%) due 
to inadequate breast thickness under compression, and two 
Fig. 4. 47-year-old female patient who underwent screening mammography.
A. Magnified mammogram of left breast reveals suspicious grouped fine pleomorphic microcalcifications (arrow). B. Ultrasonogram of left breast 
shows hypoechoic mass with internal hyperechoic foci (arrows) in upper central aspect of left breast. 14-gauge ultrasonography-guided core 
needle biopsy was performed on mass, and calcifications were not retrieved per specimen mammography. Diagnosis was stromal fibrosis, which 
was thought to be discordant with imaging findings. Patient underwent excisional biopsy under wire localization, and final diagnosis was ductal 
carcinoma in situ.
A B
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patients (0.8%) developed vasovagal reactions. Previous 
studies reported technical feasibility rates of 93–99% (18-
20) and vasovagal reaction rates of 0–2% in the prone 
position for S-VAB (12, 18). The biopsy failure rate for 
S-VAB can differ according to patient position. The prone 
position, which is used in most institutions, is reliable and 
accurate but requires significant space and is relatively 
expensive. Some institutions prefer the sitting or decubitus 
position, but they can present problems due to the 
relatively high frequency of vasovagal reactions and patient 
motion (16, 18, 21). Digital breast tomosynthesis-guided 
biopsies are performed at some institutions using the lateral 
decubitus position, and a higher biopsy success rate in less 
procedure time was reported compared with prone S-VAB 
(20). 
We had five false-negative cases; three using US-CNB 
and two for S-VAB; one case was a calcification retrieval 
failure case, three cases were detected by imaging-
histologic discordance, and the other case was detected by 
follow-up mammography. Of these five cases, four patients 
underwent repeat biopsy within 2 weeks, and the fifth 
underwent repeat biopsy 3 years later, demonstrating that 
an immediate imaging-histological correlation and long-
term follow-up are vital for confirming a benign diagnosis 
after percutaneous imaging-guided breast biopsy. Previous 
studies reported missed false-negative cases that were 
detected at follow-up mammography and obtained 6–24 
months after stereotactic biopsy (22, 23) and 6–27 months 
after US-CNB (24). The standard follow-up period after 
percutaneous breast biopsy has not been decided. Lee et al. 
(23) suggested up to 36 months of follow-up mammography 
after a nonspecific benign diagnosis by stereotactic biopsy. 
The mean follow-up period in our study was 1173.8 days 
(range, 385–1924 days), which may have been insufficient 
for confirming benign pathology in some patients. 
In the current study, the ADH underestimation rate was 
12.5% after S-VAB, which concurs with the reported range 
of 7–35% after S-VAB (10). The DCIS underestimation rates 
of US-VAB (41.7%) and S-VAB (8.6%) in the current study 
are consistent with those of previous reports (10, 12, 15, 
25, 26). However, the DCIS underestimation rate of US-CNB 
(41.7%) was higher than that of a previous report (12.5%) 
(11). This can be explained by the performance of US-CNB 
in cases of microcalcifications associated with a mass in 
which there is a higher chance of an invasive component.
Sonographically visible lesions were significantly more 
likely to be malignant (66.2% vs. 23.2%; p < 0.001) 
and have a higher BI-RADS category (61.0% vs. 22.2%; 
p < 0.001) than those not detected on US in our study, 
which concurs with previous reports that demonstrated a 
correlation between malignant pathology and visibility on 
US (5, 9, 27). The proportion of malignant pathology was 
different according to biopsy method in our study. Invasive 
carcinoma was more frequent on US-CNB (45.0%, 9/20) 
than for US-VAB (16.1%, 5/31) and S-VAB (17.4%, 8/46), 
which was due to selecting US-visible masses for US-CNB. 
Previous studies have suggested that a mass seen on US 
will likely have invasive components (5, 27). Although 
the malignancy rate was higher for US-VAB than that 
for S-VAB (58.5% vs. 23.7%), the proportion of invasive 
carcinoma was similar for US-VAB and S-VAB (16.1% vs. 
17.4%). This result suggests that the presence of US-
visible calcifications implies a more malignant pathology 
but does not increase the likelihood of invasion in cases 
with no accompanying mass. Echogenic foci within a mass 
or a ductal change is seen in DCIS on US, accompanied by 
internal microlobulations or a branch pattern distribution 
(28), so it is not surprising that visibility of calcifications 
on US is not associated with cancerous invasion. 
Our study had several limitations. First, the number of 
Table 4. Correlation of US Visibility and Histologic Diagnosis of Mammographically Detected Microcalcifications
US-Visible US-Invisible P
All pathology (n = 275) < 0.001
Benign 26/77 (33.8%) 152/198 (76.8%)
Malignant 51/77 (66.2%) 46/198 (23.2%)
BI-RADS category (n = 275) < 0.001
4a 30/77 (39.0%) 154/198 (77.8%)
4b + 4c + 5 47/77 (61.0%) 44/198 (22.2%)
Malignant pathology (n = 97)  0.334
Invasive 13/51 (25.5%) 8/46 (17.4%)
Non-invasive 38/51 (74.5%) 38/46 (82.6%)
BI-RADS = Breast Imaging Reporting and Data System, US = ultrasonography
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patients was small, and the study was performed in a single 
center. Further study with a larger number of patients 
from multiple centers is needed to compare the overall 
diagnostic outcomes of the various biopsy methods. Second, 
we set the standard follow-up period as at least 1 year for 
mammography, which may be insufficient for diagnosing 
benign microcalcifications. Lastly, breast US is an operator-
dependent procedure and reproducibility is dependent on 
individual skill of the radiologist. Inter-operator variability 
was not evaluated in this study. 
In conclusion, US-VAB was a more accurate and 
acceptable biopsy method than US-CNB when suspicious 
microcalcifications were visualized on US. Calcifications 
showing malignant pathology or lesions assigned to a 
higher BI-RADS category were significantly more visible on 
US than benign lesions or lesions assigned to a lower BI-
RADS category.
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